How I treat patients with diffuse large B-cell lymphoma.

The disease we now call diffuse large B-cell lymphoma has gone by many names in the past. These have included reticulum cell sarcoma,[1][1] diffuse histiocytic lymphoma,[2][2] and, more recently, diffuse mixed lymphoma, diffuse large cell lymphoma, or immunoblastic lymphoma—terms from the Working

[1]  W. Wilson,et al.  FDG-PET lymphoma demonstration project invitational workshop. , 2007, Academic radiology.

[2]  R. Gascoyne,et al.  Clinical Trials and Observations , 2005 .

[3]  Qian Zhou,et al.  A Cluster of Basic Residues in the Factor VIIIa A2 Subunit Function in Substrate Binding and Product Release during the Activation of Factor X by Factor Xase. , 2006 .

[4]  R. Gascoyne,et al.  Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL). , 2006 .

[5]  L. Rimsza,et al.  Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease. , 2006, Seminars in hematology.

[6]  J. Armitage,et al.  Alpha-interferon for relapsed non-Hodgkin's lymphoma , 2006, Bone Marrow Transplantation.

[7]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[9]  J. Armitage,et al.  Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Gascoyne,et al.  Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.

[11]  A. Zelenetz,et al.  Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Klapper,et al.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. , 2006, Blood.

[13]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[14]  L. Staudt,et al.  BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Hsu,et al.  Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  P. Gaulard,et al.  Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. , 2006, Haematologica.

[17]  K. Hoang-Xuan,et al.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. , 2006, Blood.

[18]  N. Schmitz,et al.  Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2005 .

[19]  T. Molina,et al.  No Role for Chemoradiotherapy When Compared with Chemotherapy Alone in Elderly Patients with Localized Low Risk Aggressive Lymphoma: Final Results of the LNH93-4 GELA Study. , 2005 .

[20]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Montoto,et al.  Secondary central nervous system lymphoma: risk factors and prophylaxis. , 2005, Hematology/oncology clinics of North America.

[22]  B. Cheson,et al.  Role of positron emission tomography in lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. O'brien,et al.  Richter's syndrome: biology and therapy. , 2005, Cancer journal.

[25]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[26]  A. Levis,et al.  High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. , 2005, Haematologica.

[27]  J. Earle,et al.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.

[29]  Dirk Hasenclever,et al.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.

[30]  W. Chan,et al.  Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. , 2004, Clinical lymphoma.

[31]  R. Gressin,et al.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.

[32]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[33]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[34]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[35]  P. Bierman,et al.  Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[37]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[38]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[39]  S. Pileri,et al.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Schmitz,et al.  An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.

[41]  F. Cavalli,et al.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  N. Schmitz,et al.  Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Cristián Zegers Ariztía,et al.  Manual , 2002 .

[44]  T. Molina,et al.  Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Staudt,et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.

[46]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[47]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[48]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[49]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[50]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[51]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[52]  H. Prince,et al.  Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. , 2001, Clinical lymphoma.

[53]  H. Kluin-Nelemans,et al.  Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.

[54]  P. Gaulard,et al.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[56]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[57]  J. Blay,et al.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.

[58]  T. Chisesi,et al.  VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[60]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[62]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[63]  F. Gherlinzoni,et al.  High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[65]  J. Cox,et al.  Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Raemaekers,et al.  Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[67]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[68]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[69]  D. Weisenburger,et al.  Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. , 1992, Blood.

[70]  K. Singh,et al.  Breast-feeding in eastern Uttar Pradesh, India: differentials and determinants. , 1991, Janasamkhya.

[71]  E. Jaffe,et al.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Pinkus,et al.  The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Connors,et al.  Testicular lymphoma: improved outcome with early brief chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Connors,et al.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. , 1987, Annals of internal medicine.

[75]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[76]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[78]  N. Nissen,et al.  A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas , 2006, Cancer.

[79]  C. Osborne,et al.  An autopsy study of histologic progression in non‐Hodgkin's lymphomas 192 cases from the national cancer institute , 1983, Cancer.

[80]  National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. , 1982, Cancer.

[81]  J. Kinzie,et al.  Survival of patients with localized diffuse histiocytic lymphoma. , 1981, Blood.

[82]  C. Coltman,et al.  Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.

[83]  H. Golomb,et al.  COMBINED THERAPY FOR SMALL-CELL CARCINOMA OF THE BRONCHUS , 1976, The Lancet.

[84]  V. Devita,et al.  ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY , 1975, The Lancet.

[85]  J. Bertino,et al.  Combination sequential chemotherapy in advanced reticulum cell sarcoma , 1972, Cancer.

[86]  Henry Rappaport,et al.  Follicular lymphoma. A re‐evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases , 1956, Cancer.

[87]  T. Mallory,et al.  Malignant Lymphoma: A Clinico-Pathologic Survey of 618 Cases. , 1942, The American journal of pathology.

[88]  M. Richter.  Generalized Reticular Cell Sarcoma of Lymph Nodes Associated with Lymphatic Leukemia. , 1928, The American journal of pathology.